(NASDAQ: OCGN) Ocugen's forecast annual revenue growth rate of 147.36% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 80.59%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.89%.
Ocugen's revenue in 2025 is $4,754,000.On average, 3 Wall Street analysts forecast OCGN's revenue for 2025 to be $1,105,788,816, with the lowest OCGN revenue forecast at $833,068,498, and the highest OCGN revenue forecast at $1,636,906,522. On average, 2 Wall Street analysts forecast OCGN's revenue for 2026 to be $949,990,392, with the lowest OCGN revenue forecast at $321,535,210, and the highest OCGN revenue forecast at $1,578,445,574.
In 2027, OCGN is forecast to generate $29,704,007,272 in revenue, with the lowest revenue forecast at $29,704,007,272 and the highest revenue forecast at $29,704,007,272.